TRANSFORMING
CANCER
DIAGNOSTICS
WITH AI

Since 2016, Ibex has led the way in AI-powered diagnostics for pathology.

We set out to transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.

Today, we are by far the most widely-deployed artificial intelligence platform in pathology. Developed by pathologists for pathologists, our solutions serve the world’s leading physicians, healthcare organizations and diagnostic providers—supporting the precise detection, grading, and classification of complex cases, including breast, prostate, lung and gastric cancers for both H&E and IHC staining.

Every day, we have the privilege of touching the lives of patients worldwide. We raise physician confidence, streamline diagnostic workflows, help clinicians provide more personalized diagnosis and, most importantly, enable better clinical outcomes for patients.

 Ibex partners with top pharma organizations to develop AI-powered quantification and scoring solutions for complex IHC biomarkers. Our Biopharma offering is built on a foundation of clinical leadership and technical excellence. It is designed to offer end-to-end support for pharma, from initial biomarker development through global regulatory clearances to real-world clinical availability at scale.